S&P 500 Healthcare Sector SEC Filings — February 05, 2026

06-02-2026

Catheter Precision, Inc. filed a multi-item Form 8-K on February 6, 2026, disclosing entry into a material definitive agreement (Item 1.01), unregistered sales of equity securities (Item 3.02), material modifications to rights of security holders (Item 3.03), and amendments to articles of incorporation or bylaws (Item 5.03), with exhibits under Item 9.01. These events suggest potential financing, dilution, and governance changes, but no specific transaction values, share counts, dollar amounts, or financial impacts are disclosed. No positive or negative metrics such as revenue, earnings, or balance sheet effects are mentioned.

06-02-2026

News Corp filed an 8-K on February 6, 2026 (AccNo: 0001564708-26-000028, Size: 399 KB), reporting under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). No specific details on the nature of the other events or contents of the exhibits are disclosed. This is a multi-item informational filing with no quantified financial metrics, positive or negative changes, or directional indicators provided.

06-02-2026

Centene Corp filed an 8-K on February 6, 2026, under Item 2.02 disclosing results of operations and financial condition, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, margins, guidance, or period-over-period comparisons were detailed in the provided filing information. This appears to be a standard earnings-related disclosure without quantified metrics.

06-02-2026

Pulse Biosciences, Inc. filed a Form 8-K on February 6, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the nature of the other events, any financial statements, exhibits, transaction values, metrics, or impacts are disclosed in the provided filing summary.

06-02-2026

Newell Brands Inc. filed an 8-K on February 6, 2026, under Item 2.02 disclosing Results of Operations and Financial Condition, accompanied by Item 9.01 for Financial Statements and Exhibits. No specific revenue, earnings, margins, period-over-period changes, guidance, or other quantitative financial metrics are mentioned in the provided filing details. This is a standard voluntary earnings-related disclosure with no directional financial data available.

06-02-2026

Biogen Inc. filed an 8-K on February 6, 2026, disclosing results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, guidance, or other quantitative financial metrics are disclosed in the provided filing information. This appears to be a standard voluntary earnings-related disclosure without detailed performance data.

06-02-2026

Roivant Sciences Ltd. filed an 8-K on February 6, 2026 (AccNo: 0001635088-26-000009, Size: 391 KB), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific revenue, earnings, balance sheet details, period-over-period comparisons, guidance, or other quantitative financial metrics are disclosed in the provided filing information.

06-02-2026

UMeWorld Inc. filed an 8-K on February 6, 2026, disclosing changes in its certifying accountant under Item 4.01. No financial metrics, transaction values, dollar amounts, percentages, or details on the nature of the change (e.g., resignation, dismissal, disagreements) are mentioned. No positive or negative performance metrics are reported.

06-02-2026

OneWater Marine Inc. filed an 8-K on 2026-02-06 disclosing entry into a material definitive agreement under Item 1.01 and completion of an acquisition or disposition of assets under Item 2.01. Item 9.01 provides financial statements and exhibits. No specific transaction details, parties, values, or metrics are disclosed.

06-02-2026

Fannie Mae filed an 8-K on February 6, 2026, specifically reporting Item 5.07: Submission of Matters to a Vote of Security Holders. No specific proposals, voting results, financial metrics, or other quantitative details are disclosed in the provided filing information. This is an informational disclosure with no directional financial impact evident.

06-02-2026

Arcadia Biosciences, Inc. filed an 8-K on 2026-02-06 disclosing an officer or director change under Item 5.02, covering departures, elections, appointments, or compensatory arrangements of certain officers. The filing includes Item 9.01 for financial statements and exhibits. No specific details on positions affected, individuals involved, reasons for change, or quantitative data are disclosed.

06-02-2026

iSpecimen Inc. filed an 8-K on February 6, 2026 (AccNo: 0001213900-26-013265), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This multi-item filing represents a voluntary disclosure likely including material non-public information via attached exhibits. No quantitative financial metrics, transaction details, guidance, or period-over-period comparisons are disclosed in the filing metadata.

06-02-2026

Acacia Research Corp filed an 8-K on 2026-02-06 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals involved, reasons for changes, or any quantitative data such as compensation amounts are provided in the filing summary. Sector is not specified.

06-02-2026

Cingulate Inc. filed an 8-K on February 6, 2026, reporting Item 3.02 Unregistered Sales of Equity Securities and Item 8.01 Other Events. This is a multi-item filing with no specific transaction details, dollar values, share counts, or financial impacts disclosed. No positive or negative metrics, guidance changes, or scheduled events are mentioned.

06-02-2026

Edgewell Personal Care Co filed an 8-K on February 6, 2026, announcing under Item 2.01 the completion of an acquisition or disposition of assets. The filing also includes Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific transaction details, financial metrics, parties involved, or values are disclosed.

06-02-2026

Hewlett Packard Enterprise Co filed an 8-K on 2026-02-06 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). No specific details on the affected position, individual names, appointment or resignation status, reasons, or compensatory terms are disclosed. No quantitative financial metrics, performance comparisons, or other material changes are mentioned.

06-02-2026

Commercial Vehicle Group, Inc. filed a Form 8-K on February 6, 2026, reporting under Item 1.01 entry into a material definitive agreement, under Item 5.02 departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers, under Item 7.01 Regulation FD disclosure, and under Item 9.01 financial statements and exhibits. This is a multi-item filing with no specific details on the agreement, personnel changes, or disclosures provided in the available information. No quantitative financial impacts, transaction values, or other metrics are disclosed.

06-02-2026

CAPITAL ONE FINANCIAL CORP filed an 8-K on 2026-02-06 disclosing an officer change under Item 5.02, covering departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. Item 9.01 references financial statements and exhibits. No specific details on affected positions, individuals, reasons, or quantitative impacts are disclosed.

06-02-2026

Lexaria Bioscience Corp. filed a Form 8-K on 2026-02-06 under Item 3.01, providing notice of delisting or failure to satisfy a continued listing rule or standard, or transfer of listing. No quantitative financial metrics, transaction values, period-over-period comparisons, or other numerical data disclosed in the available information. This event indicates a material negative development with no offsetting positive metrics reported.

06-02-2026

Enveric Biosciences, Inc. filed a Form 8-K on February 06, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the nature of the other events, transaction values, financial metrics, or exhibits are disclosed in the filing summary. No positive or negative metrics are mentioned.

06-02-2026

Werewolf Therapeutics, Inc. filed a Form 8-K on 2026-02-06 under Item 3.01, announcing a notice of delisting or failure to satisfy a continued listing rule or standard, or transfer of listing. No financial metrics, transaction values, or additional details such as reasons for delisting, impacts, or future plans were disclosed.

• ·Accession Number: 0001193125-26-041305
• ·File Size: 144 KB
• ·Sector: not specified

06-02-2026

Webster Financial Corp filed an 8-K on February 6, 2026, reporting under Item 1.01 entry into a Material Definitive Agreement and under Item 9.01 Financial Statements and Exhibits. No financial metrics, transaction details, positive or negative impacts, or period-over-period comparisons are disclosed. This is an informational filing with limited specifics available.

06-02-2026

Society Pass Incorporated filed a Form 8-K on February 6, 2026, under Item 8.01 Other Events. The specific nature of the other event is NOT_DISCLOSED in the provided filing information. No financial metrics, transactions, or quantitative data are mentioned.

06-02-2026

Twist Bioscience Corp filed a Form 8-K on February 6, 2026 (AccNo: 0001581280-26-000022), reporting under Item 5.07 the submission of matters to a vote of security holders. No specific proposals, vote outcomes, tally details, or other metrics are disclosed. This is a routine post-shareholder meeting disclosure with no financial or operational impacts mentioned.